Loading…
Stop Meth Labs and Enhance Patient Access Act of 2014
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
71pct
42d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2014 · third_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; general issues related to health care reform; and all general issues related to the 21st Century Cures Initiative.
Client expense: $940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Tariff (miscellaneous tariff bills)
Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Tariff (miscellaneous tariff bills)
Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Tariff (miscellaneous tariff bills)
Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Tariff (miscellaneous tariff bills)
Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). H.R. 4502 - Stop Meth Labs and Enhance Patient Access Act of 2014 (all sections). Would grant additional authority to the Drug Enforcement Administration (DEA) to grant exemptions to the provisions of the Combat Methamphetamine Epidemic Act of 2005 (P.L. 109-177). Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R. 4250/S. 2141 - Sunscreen Innovation Act. Would require FDA to approve or deny new sunscreen ingredient applications under the "time and extent" application (TEA) process within a certain timeframe after submission; all sections.
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act. H.R. 4502: Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and coldmedicines that contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Client expense: $840,000 · Firm income: Not reported
2014 · fourth_quarter · Pharmacy
General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014. Issues related to pediatric flow restrictors; Issues related to Energy and Commerce draft of "21st Century Cures."
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2014 · third_quarter · Health Issues
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient protection and Affordable Care Act. Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development. H.R. 4502, Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicinesthat contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Tariff (miscellaneous tariff bills)
MTBs - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505) (S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · fourth_quarter · Tariff (miscellaneous tariff bills)
MTBs discussions generally - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) (S. 3055, S.3056, S. 3057, S. 3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Tariff (miscellaneous tariff bills)
MTBs - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) ( S. 2399, S. 2400, S. 2401, S. 2402, S. 2403, S. 3055, S. 3056, S. 3057, S.3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043) Technical Correction - (S. 3073) Sleeping bag shells/carrying cases - (H.R. 4973, H.R. 4974, H.R. 4975) Travel/Cargo/Duffel/Rolling Backpack Bags - (H.R. 5034, H.R. 5631, H.R. 5632, H.R. 5633, H.R. 5634, H.R. 5635, H.R. 5636) (S. 2621)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · third_quarter · Tariff (miscellaneous tariff bills)
MTBs - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505) (S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · third_quarter · Tariff (miscellaneous tariff bills)
MTBs - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) ( S. 2399, S. 2400, S. 2401, S. 2402, S. 2403, S. 3055, S. 3056, S. 3057, S.3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043); Technical Correction - (S. 3073); Sleeping bag shells/carrying cases - (H.R. 4973, H.R. 4974, H.R. 4975); Travel/Cargo/Duffel/Rolling Backpack Bags - (H.R. 5034, H.R. 5631, H.R. 5632, H.R. 5633, H.R. 5634, H.R. 5635, H.R. 5636) (S. 2621)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · third_quarter · Tariff (miscellaneous tariff bills)
MTBs discussions generally - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) (S. 3055, S.3056, S. 3057, S. 3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act. H.R. 4502: Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014."General issues related to the 21st Century Cures Initiative.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2014 · third_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continuedover-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; general issues related to health care reform; and all general issues related to the 21st Century Cures Initiative.
Client expense: $940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act. H.R. 4502: Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic track- ing system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · second_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014."
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"
Client expense: $720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · second_quarter · Tariff (miscellaneous tariff bills)
MTBs Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505) ( S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · second_quarter · Tariff (miscellaneous tariff bills)
MTBs: Footwear: (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) ( S. 2399, S. 2400, S. 2401, S. 2402, S. 2403, S. 3055, S. 3056, S. 3057, S.3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043); Technical Correction - (S. 3073); Sleeping bag shells/carrying cases: (H.R. 4973, H.R. 4974, H.R. 4975); Travel/cargo/duffel/rolling backpack bags (HR 5034, HR 5631, HR 5632, HR 5633, HR 5634,H.R. 5635, H.R. 5636) (S. 2621).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2014 · second_quarter · Tariff (miscellaneous tariff bills)
MTB discussions generally; Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) (S. 3055, S.3056, S. 3057, S. 3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Tariff (miscellaneous tariff bills)
Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505) ( S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · first_quarter · Tariff (miscellaneous tariff bills)
Footwea: (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) ( S. 2399, S. 2400, S. 2401, S. 2402, S. 2403, S. 3055, S. 3056, S. 3057, S.3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043); Technical Correction - (S. 3073); Sleeping bag shells/carrying cases: (H.R. 4973, H.R. 4974, H.R. 4975);Travel/Cargo/Duffel/Rolling Backpack Bags - (H.R. 5034, H.R. 5631, H.R. 5632, H.R. 5633, H.R. 5634, H.R. 5635, H.R. 5636) (S. 2621).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2014 · first_quarter · Tariff (miscellaneous tariff bills)
Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505, H.R. 4993, H.R. 4994, H.R. 4995, H.R. 5330) (S. 3055, S.3056, S. 3057, S. 3058, S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2014 · first_quarter · Trade (domestic/foreign)
Check all international trade legislation, and in particular lobby for Affordable Footwear Act, Miscellaneous Tariff bill, reinstatement of duty suspension for specific footwear, as well as funding for AmeriCorps. TAR (MTBs): Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Tariff (miscellaneous tariff bills)
Check all international trade legislation, and in particular lobby for Affordable Footwear Act, Miscellaneous Tariff bill, reinstatement of duty suspension for specific footwear, as well as funding for AmeriCorps. TAR (MTBs): Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Tariff (miscellaneous tariff bills)
MTBs - Footwear - (H.R. 4926, H.R. 4927, H.R. 4928, H.R. 4929, H.R. 4502, H.R. 4503, H.R. 4504, H.R. 4505) ( S. 3036, S. 3037, S. 3038, S. 3039, S. 3040, S. 3041, S. 3042, S. 3043)
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)
2013 · fourth_quarter · Trade (domestic/foreign)
Check all international trade legislation, and in particular lobby for Affordable Footwear Act, Miscellaneous Tariff bill, reinstatement of duty suspension for specific footwear, as well as funding for AmeriCorps. TAR (MTBs): Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Tariff (miscellaneous tariff bills)
Check all international trade legislation, and in particular lobby for Affordable Footwear Act, Miscellaneous Tariff bill, reinstatement of duty suspension for specific footwear, as well as funding for AmeriCorps. TAR (MTBs): Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · second_quarter · Tariff (miscellaneous tariff bills)
Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · first_quarter · Tariff (miscellaneous tariff bills)
Lobbied on bills S.3037 - S.3043 and H.R.4502, H.R.4503, H.R.4929, H.R.4928, H.R.4504, H.R.4505, H.R.4927, and H.R.4926.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE